Journal of Clinical Movement Disorders最新文献

{"title":"Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy.","authors":"Dirk Dressler,&nbsp;Fereshte Adib Saberi","doi":"10.1186/s40734-017-0049-z","DOIUrl":"https://doi.org/10.1186/s40734-017-0049-z","url":null,"abstract":"<p><strong>Background: </strong>AbobotulinumtoxinA (Dysport®) was distributed for many years in vials containing 500MU (D500). Recently a new 300MU vial (D300) was additionally introduced (introduction). We wanted to explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic.</p><p><strong>Methods: </strong>The study followed a retrospective chart review design based on our digital BT therapy data bank. All patients receiving Dysport® exclusively in a constant dose during the observation period (introduction ± 7 months) were included. Economic calculations are based on Dysport® prices as officially advertised in Germany. Sharing of vials between patients was not allowed.</p><p><strong>Results: </strong>Altogether 83 patients (51 with dystonia, 25 with spasticity, 3 with hemifacial spasm, 4 with other diagnoses) were included in this study. The total amount of BT used before and after introduction was 102525MU, the amount prescribed 138000MU and 116300MU (-21700MU, -15.7%), the costs €146103 and €125250 (-€ 20853, -14.3%). The price for D500 before and after introduction was €529.36, for D300 €339.71. The D500 price for 1MU before and after introduction is €1.0587, the D300 price for 1MU €1.1324 (+ €0.073, +7.0% against D500).</p><p><strong>Conclusions: </strong>More flexible packaging reduces drug costs for BT therapy considerably. Introducing smaller packaging sizes is technically possible and should be encouraged. Extra costs for registration and logistics are moderate. Further cost reductions may be possible by introduction of even smaller packaging sizes. They can be calculated based on our model.</p>","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"4 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2017-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40734-017-0049-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34961360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation and care of a family with Huntington disease in a resource-limited community.","authors":"Jarmal Charles,&nbsp;Lindyann Lessey,&nbsp;Jennifer Rooney,&nbsp;Ingmar Prokop,&nbsp;Katherine Yearwood,&nbsp;Hazel Da Breo,&nbsp;Patrick Rooney,&nbsp;Ruth H Walker,&nbsp;Andrew K Sobering","doi":"10.1186/s40734-017-0050-6","DOIUrl":"https://doi.org/10.1186/s40734-017-0050-6","url":null,"abstract":"<p><strong>Background: </strong>In high-income countries patients with Huntington disease (HD) typically present to healthcare providers after developing involuntary movements, or for pre-symptomatic genetic testing if at familial risk. A positive family history is a major guide when considering the decision to perform genetic testing for HD, both in affected and unaffected patients. Management of HD is focused upon control of symptoms, whether motor, cognitive, or psychiatric. There is no clear evidence to date of any disease-modifying agents. Referral of families and caregivers for psychological and social support, whether to HD-focused centers, or through virtual communities, is viewed as an important consequence of diagnosis. The experience of healthcare for such progressive neurodegenerative diseases in low- and middle-income nations is in stark contrast with the standard of care in high-income countries.</p><p><strong>Methods: </strong>An extended family with many members affected with an autosomal dominantly inherited movement disorder came to medical attention when one family member presented following a fall. Apart from one family member who was taking a benzodiazepine for involuntary movements, no other affected family members had sought medical attention. Members of this family live on several resource-limited Caribbean islands. Care of the chronically ill is often the responsibility of the family, and access to specialty care is difficult to obtain, or is unavailable. Computed tomography scan of one patient's brain revealed severe caudate atrophy and moderate generalized cortical atrophy. Genetic diagnosis of HD was obtained.</p><p><strong>Results: </strong>Through family recollection and by direct observation we identified four generations of individuals affected with HD. Outreach programs and collaborations helped to provide medical imaging and genetic diagnosis. Additionally these efforts helped with patient and family support, education, and genetic counseling to many members of this family.</p><p><strong>Conclusions: </strong>Affected members of this family have limited healthcare access, and rely heavily on family support for care. Genetic and clinical diagnosis of these patients was impeded by lack of resources and lack of access to specialty care. Importantly, obtaining a definitive diagnosis has had a positive impact for this family by facilitating genetic counseling, education, community outreach, and dispelling myths regarding this hereditary disease and its progression.</p>","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"4 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2017-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40734-017-0050-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34918926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road.","authors":"Russell P Sawyer,&nbsp;Federico Rodriguez-Porcel,&nbsp;Matthew Hagen,&nbsp;Rhonna Shatz,&nbsp;Alberto J Espay","doi":"10.1186/s40734-017-0052-4","DOIUrl":"https://doi.org/10.1186/s40734-017-0052-4","url":null,"abstract":"<p><strong>Background: </strong>Disruption of the frontal lobes and its associated networks are a common consequence of neurodegenerative disorders. Given the wide range of cognitive, behavioral and motor processes in which the frontal lobes are involved, there can be a great variety of manifestations depending on the pathology distribution. The most common are the behavioral variant of frontotemporal dementia (bvFTD) and the frontal variant of Alzheimer's disease (fvAD), which are particularly challenging to disentangle. Recognizing fvAD from bvFTD-related pathologies is a diagnostic challenge and a critical need in the management and counseling of these patients.</p><p><strong>Case presentation: </strong>Here we present three pathology-proven cases of Alzheimer's disease initially misdiagnosed as bvFTD and discuss the distinctive or less overlapping historical, examination, and laboratory findings of fvAD and bvFTD, deriving analogies for mnemonic endurance from the Wizard of Oz worldview.</p><p><strong>Conclusion: </strong>The Yellow Brick Road to diagnosing these disorders may be served by the metaphor of fvAD as the irritable, paranoid, and tremulous Scarecrow and bvFTD the heartless, ritualistic, and rigid Tin Man. An Oz-inspired creative license may help the clinician recognize the differential disease progression, caregiver burden, and treatment response of fvAD compared with bvFTD.</p>","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"4 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2017-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40734-017-0052-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34787755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.","authors":"Daniel O Claassen,&nbsp;Benjamin Carroll,&nbsp;Lisa M De Boer,&nbsp;Eric Wu,&nbsp;Rajeev Ayyagari,&nbsp;Sanjay Gandhi,&nbsp;David Stamler","doi":"10.1186/s40734-017-0051-5","DOIUrl":"https://doi.org/10.1186/s40734-017-0051-5","url":null,"abstract":"<p><strong>Background: </strong>Vesicular monoamine transporter 2 (VMAT2) inhibitors can improve hyperkinetic movements, and are effective treatment options for chorea of Huntington disease (HD). Tetrabenazine was assessed for treating chorea in the TETRA-HD trial, and while efficacious, there are tolerability concerns possibly due to its pharmacokinetic properties. Deutetrabenazine is a novel VMAT2 inhibitor that contains deuterium, which extends active metabolite half-lives and minimizes drug concentration fluctuations. In the First-HD trial, deutetrabenazine was efficacious in treating chorea and was generally well tolerated. In the absence of a head-to-head trial, we performed an indirect treatment comparison (ITC) of the tolerability of deutetrabenazine and tetrabenazine for the treatment of HD-associated chorea, as observed in the First-HD and TETRA-HD trials, using well-established comparison methods.</p><p><strong>Methods: </strong>Data from the Phase III, 12-week, parallel-group, clinical trials First-HD (<i>N</i> = 90) and TETRA-HD (<i>N</i> = 84) were used to conduct an ITC of the tolerability of deutetrabenazine versus tetrabenazine using two anchor-based methods: Bucher comparison for unadjusted ITCs, and matching indirect comparison for adjusted ITCs. Overall adverse events (AEs; mild, moderate, and severe), serious AEs, specific AEs occurring in ≥10% of patients, and discontinuations (all-cause and AE-related) were included in the analysis. The risk differences of these outcomes for deutetrabenazine and tetrabenazine were estimated by subtracting the applicable placebo-adjusted risk in First-HD from that of TETRA-HD. Sensitivity analyses were performed to address differences between trials, and <i>p</i>-values were obtained from z-tests.</p><p><strong>Results: </strong>Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (<i>p</i> < 0.05 for each). Deutetrabenazine had a significantly lower rate of dose reduction or dose reduction/suspension in the unadjusted and adjusted analyses (<i>p</i> < 0.001 for each). Deutetrabenazine resulted in numerically more mild AEs, such as diarrhea and coughing; however, these results were not statistically significant.</p><p><strong>Conclusions: </strong>This indirect treatment comparison demonstrates that for the treatment of HD chorea, deutetrabenazine has a favorable tolerability profile compared to tetrabenazine.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT01795859 and NCT00219804.</p>","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"4 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40734-017-0051-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34787756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons I have learned from my patients: everyday life with primary orthostatic tremor","authors":"M. Vidailhet, E. Roze, Lucie Maugest, C. Galléa","doi":"10.1186/s40734-016-0048-5","DOIUrl":"https://doi.org/10.1186/s40734-016-0048-5","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88396108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher’s Erratum: Spinal-generated movement disorders: a clinical review","authors":"P. Termsarasab, Thananan Thammongkolchai, S. Frucht","doi":"10.1186/s40734-016-0042-y","DOIUrl":"https://doi.org/10.1186/s40734-016-0042-y","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87379149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel gene (TMEM230) linked to Parkinson’s disease","authors":"D. Olszewska, Conor Fearon, T. Lynch","doi":"10.1186/s40734-016-0046-7","DOIUrl":"https://doi.org/10.1186/s40734-016-0046-7","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75900847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Pearls - how my patients taught me: The fainting lark symptom","authors":"A. Kuiper, M. V. van Egmond, M. Harms, M. Oosterhoff, B. van Harten, D. Sival, T. D. de Koning, M. Tijssen","doi":"10.1186/s40734-016-0045-8","DOIUrl":"https://doi.org/10.1186/s40734-016-0045-8","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73777343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phenomenology and treatment of idiopathic adult-onset truncal dystonia: a retrospective review","authors":"D. Ehrlich, S. Frucht","doi":"10.1186/s40734-016-0044-9","DOIUrl":"https://doi.org/10.1186/s40734-016-0044-9","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"44 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80442649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding article ‘Freezing of gait associated with a corpus callosum lesion’","authors":"H. Onder","doi":"10.1186/s40734-016-0041-z","DOIUrl":"https://doi.org/10.1186/s40734-016-0041-z","url":null,"abstract":"","PeriodicalId":15374,"journal":{"name":"Journal of Clinical Movement Disorders","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87955189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}